Cervical Cancer. Gardasil human papillomavirus vaccine [types 6, 11, 16, 18] recombinant, adsorbed [Internet]. Long-term persistence of anti-VPH and antibodies induced by vaccination with the ASadjuvanted cervical cancer vaccine: modeling of sustained antibody responses. Gynecol Oncol. Chen RT. Vaccine risks: real, perceived and unknown.
The Pediatric Infectious Disease Journal. Autoimmune, neurological, and venous thromboembolic adverse events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in Denmark and Sweden: Cohort study. British Medical Journal.
The American College of Obstetricians and Gynecologists. Committee opinion. Human Papillomavirus Vaccination. Int J Cancer. Efficacy and safety of human papillomavirus vaccine for primary prevention of cervical cancer: a review of evidence from phase III trials and national programs.
South Asian J Cancer. Vacunas contra el Virus del Papiloma Humano [Internet]. Consensus Statement. Early experience with human papillomavirus vaccine introduction in the United States, Canada and Australia. Human papillomavirus and cervical cancer in Australasia and Oceania: risk-factors, epidemiology and prevention.
The epidemiology of human papillomavirus infections. J Clin Virol. Human papillomavirus infection and cervical cancer prevention in India, Bangladesh, Sri Lanka and Nepal. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus types 6, 11, 16, 18 recombinant vaccine in women aged years: a randomised, double-blind trial.
Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant. J Adolesc Health. Human papillomavirus vaccination for the prevention of cervical neoplasia: is it appropriate to vaccinate women older than 26?
Med J Aust. Protocol Study Group. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus types 6, 11, 16, and 18 L1 virus-like particle vaccine in male and female adolescents and young adult women. Fleider L. Ministerio de Salud de Chile.
Gobierno de Argentina. Julio de [Internet]. Comunicado [Internet]. Brotherton JM. Human papillomavirus vaccination: Where are we now? J Paediatr Child Health. La inmunidad celular ejerce un papel determinante en las enfermedades asociadas al VPH. En estudio retrospectivo realizado por Fakhry y col. Hay evidencias que van en favor y estudios que revelan lo contrario. Prakash S y col. Antonsson y col. El efecto de la TAAE en estas lesiones pre invasoras es controversial.
Varios estudios prospectivos recientes han documentado que la persistencia del VPH entre las mujeres infectadas por el VIH es mayor que en aquellas no infectadas por el VIH. Estos datos incluyen tanto hombres y mujeres VIH positivos; si se incluyen solamente los hombres, esta incidencia es mucho mayor. Human papilllomavirus and associated malignancies. J Clin Oncol. The viral etiology of AIDS-associated malignancies.
Adv Pharmacol. Int J Mol Med. J Tumor Marker Oncol. Gynecol Oncol. Human papillomavirus HPV type distribution in cervical carcinoma, low-grade, and high- grade squamous intraepithelial lesions in Venezuelan women. Human papillomavirus detection in head and neck squamous cell carcinoma. Ecancermedicalscience ; Fakhry C, Gillison ML. Clinical implication of human papillomavirus in head and neck cancers. Human papillomavirus and overall survival after progression of oropharyngeal squamous cell carcinoma.
Parkin DM. The global health burden of infection- associated cancers in the year Int J Cancer. Penile cancer: Epidemiology, pathogenesis and prevention.
0コメント